Central to recent debates about disinfectant
validation is whether value is added by
individual facilities performing studies, or
if a large central study could be relied upon
to demonstrate the efficacy of biocides.
Regulators expect disinfectant validation to
be conducted by facilities in the pharmaceutical,
biotech, medical device and 503B
compounding pharmacy industries. As
regulators look more closely at disinfectant
validation, the role of the surface in the
disinfectant process has been heightened.